Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2022 Results and Participation in Upcoming Investor Conferences

Rhea-AI Summary

SANTA CLARA, Calif., April 27, 2022 – Shockwave Medical, Inc. (NASDAQ: SWAV) will announce its Q1 2022 financial results after market close on May 9, 2022. A conference call will follow at 1:30 p.m. PT. Additionally, management will participate in a fireside chat at the BofA Securities Healthcare Conference on May 11, 2022, at 3:20 p.m. PT, and at the UBS Global Healthcare Conference on May 23, 2022, at 8:30 a.m. ET. Interested parties can access these events via the Investors section on the company’s website.

SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, May 11, 2022, at 3:20 p.m. Pacific Time, Shockwave Medical management is scheduled for a fireside chat at the BofA Securities 2022 Healthcare Conference, which is taking place on Tuesday, May 10 - Thursday, May 12, 2022 at the Encore Hotel in Las Vegas, NV.

On Monday, May 23, 2022, at 8:30 a.m. Eastern Time, Shockwave Medical management is scheduled for a fireside chat at the UBS Global Healthcare Conference 2022 taking place at the Lotte New York Palace on Monday, May 23 - Wednesday, May 25, 2022.

Interested parties may access live and archived webcasts of these events on the "Investors" section of the company’s website at https://ir.shockwavemedical.com.  Investors interested in listening to the first quarter 2022 Shockwave Medical earnings conference call on Monday May 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 7258221.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com

FAQ

When will Shockwave Medical release its Q1 2022 financial results?

Shockwave Medical will report its Q1 2022 financial results after market close on May 9, 2022.

What time is the conference call for Shockwave Medical's Q1 earnings?

The conference call for Shockwave Medical's Q1 earnings will begin at 1:30 p.m. Pacific Time on May 9, 2022.

Where can I find the webcast for Shockwave Medical's events?

Webcasts for Shockwave Medical's events can be accessed in the Investors section of their website.

What events will Shockwave Medical participate in during May 2022?

Shockwave Medical will participate in the BofA Securities Healthcare Conference on May 11 and the UBS Global Healthcare Conference on May 23, 2022.

What is Intravascular Lithotripsy (IVL) developed by Shockwave Medical?

Intravascular Lithotripsy (IVL) is a technique developed by Shockwave Medical to treat calcified cardiovascular disease using sonic pressure waves.